ABSTRACT
Introducción: la desnutrición es un problema frecuente en los pacientes oncológicos que empeora durante la hospitalización y se asocia con mayor morbimortalidad y deterioro de la calidad de vida. Objetivos: describir el efecto de la implantación de un protocolo de valoración y soporte nutricional sobre el estado nutricional de pacientes oncológicos hospitalizados. Métodos: estudio prospectivo, no controlado y cuasiexperimental en pacientes oncológicos ingresados en un servicio de oncología de forma consecutiva, independientemente de su estado nutricional, entre septiembre de 2019 y marzo de 2020. Se determinaron los parámetros antropométricos, la composición corporal y la fuerza prensora de la mano al ingreso y al alta. Se calculó el porcentaje de pacientes con desnutrición, dinapenia y sarcopenia al ingreso y al alta. Resultados: un total de 90 pacientes oncológicos participaron en este estudio (edad media: 66 años, 67,8 % hombres). El 33,2 % de los pacientes presentaban un tumor en el tracto gastrointestinal y el 73,3 % de los pacientes se encontraban en estadio IV. El 95 % necesitaron soporte nutricional (suplementación nutricional, nutrición enteral o nutrición parenteral). Tras la intervención nutricional no se encontraron diferencias en los parámetros antropométricos, con una pérdida de peso media de 0,1, aunque se observaron mejorías en la composición corporal. El porcentaje de pacientes desnutridos se mantuvo estable al ingreso y al alta independientemente del criterio empleado Conclusiones: la implementación de un protocolo de valoración y soporte nutricional al ingreso en pacientes oncológicos puede ayudar a evitar o retrasar el empeoramiento de su estado nutricional durante la hospitalización. (AU)
Introduction: Malnutrition is a common problem in cancer patients that worsens during hospitalization and is associated with increased morbidity and mortality, and impaired quality of life. Objectives: to describe the effect of implementing a Nutritional assessment and support protocol on the Nutritional status of hospitalized cancer patients. Methods: a prospective, cross-sectional, non-controlled, quasi-experimental study in cancer patients admitted to an oncology service consecutively regardless of their Nutritional status between September 2019 and March 2020. Anthropometric parameters, body composition, and hand grip strength were measured at admission and discharge. The percentage of patients with Malnutrition, dynapenia, and sarcopenia at admission and discharge was calculated. Results: a total of 90 cancer patients participated in this study (mean age: 66 years, 67.8 % men); 33.2 % of the patients had a tumor in the gastrointestinal tract and 73.3 % of the patients were in stage IV; 95 % required Nutritional support (nutritional supplementation, enteral nutrition or parenteral nutrition). After the nutritional intervention, no differences were found in the anthropometric parameters with a mean weight loss of 0.1, although improvements in body composition were observed. The percentage of malnourished patients remained stable on admission and discharge regardless of the criteria used. Conclusions: the implementation of a protocol for assessment and nutritional support at admission in cancer patients may help prevent or delay the worsening of their nutritional status during hospital stay. (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Malnutrition , Neoplasms , Prospective Studies , Epidemiology, Descriptive , Nutritional Status , Nutrition Assessment , Body CompositionABSTRACT
Background: Non-ablative fractional laser treatments for improving skin tone and rejuvenation have become increasingly popular due to short downtime and fewer side effects compared to ablative treatments. Objective: We sought to determine the efficacy of a non-ablative 1540-nm fractional erbium: glass laser in improving skin roughness and skin texture. Methods: The forehead, cheek, and nasal areas of 15 patients were treated for five monthly sessions using a 7x7 pixel tip (1.21cm2 affective area, approximately 300 microns diameter per pixel), fluence of 2,500 to 3,000 mJ/pulse (40-62 mJ/Pixel), and three stacked pulses were emitted at a rate of 1Hz for three passes per treatment session. Measurements of skin roughness, skin roughness area, and maximum skin depth were collected using a 3D imaging system. Improvement in skin parameters was calculated by comparing the measurements prior to treatment and 12 weeks after completion. Results: All 15 patients showed significant improvement in all three measured parameters (p<0.001) with no significant side effects. Limitations: The limitations of this study include the small number of patients and the narrow range of skin tone (Fitzpatrick Skin Types II-IV). Conclusion: Our results suggest that monthly treatments with a non-ablative 1540-nm fractional Erbium:glass laser appear to be safe and effective for skin texture and roughness.
ABSTRACT
Information regarding the safety of biological drugs prescribed to psoriasis patients on daily and long-term bases is insufficient. We used data from the BIOBADADERM registry (Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases) to generate crude rates of infection during therapy with systemic drugs, including biological drugs (infliximab, etanercept, adalimumab, and ustekinumab) and nonbiological drugs (acitretin, cyclosporine, and methotrexate). We also calculated unadjusted and adjusted risk ratios (RRs) (with propensity score adjustment) of infection, serious infections, and recurrent infections of systemic therapies compared with methotrexate, using Poisson regression. Our study included records of 2,153 patients (7,867.5 person-years). The adjusted RR of overall infection was significantly increased in the groups treated with adalimumab with methotrexate (adjusted RR = 2.13, 95% confidence interval [CI] = 1.2-3.7), infliximab (adjusted RR = 1.71, 95% CI = 1.1-2.65), cyclosporine (adjusted RR = 1.58, 95% CI = 1.17-2.15), ustekinumab with methotrexate (adjusted RR = 1.56, 95% CI = 1.08-2.25), and etanercept (adjusted RR = 1.34, 95% CI: 1.02-1.76) compared with methotrexate alone. Cyclosporine had a significant risk of serious infection (adjusted RR = 3.12, 95% CI = 1.1-8.8), followed by adalimumab combined with methotrexate (adjusted RR = 3.28, 95% CI = 0.8-13.5). Adalimumab in combination with methotrexate had the highest risk of infection recurrence (adjusted RR = 4.33, 95% CI = 2.27-8.24).
